View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 09, 2018
Document Information [Line Items]
Entity Registrant Name	Diffusion Pharmaceuticals Inc.
Entity Central Index Key	0001053691
Trading Symbol	dffn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		50,572,001
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 12,934,703	$ 8,896,468
Prepaid expenses, deposits and other current assets	772,736	769,946
Total current assets	13,707,439	9,666,414
Property and equipment, net	405,925	460,652
Intangible asset	8,639,000	8,639,000
Goodwill	6,929,258	6,929,258
Other assets	262,214	450,491
Total assets	29,943,836	26,145,815
Current liabilities:
Current portion of convertible debt		550,000
Accounts payable	175,772	511,956
Accrued expenses and other current liabilities	512,246	1,628,851
Total current liabilities	688,018	2,690,807
Deferred income taxes	1,955,746	2,223,678
Other liabilities		1,386
Total liabilities	2,643,764	4,915,871
Commitments and Contingencies (Note 7)
Convertible preferred stock, $0.001 par value: Series A - 13,750,000 shares authorized at both June 30, 2018 and December 31, 2017. No shares and 12,376,329 shares issued at June 30, 2018 and December 31, 2017, respectively. No shares and 8,306,278 shares outstanding at June 30, 2018 and December 31, 2017, respectively.	0	0
Stockholders’ Equity:
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 50,572,001 and 14,519,629 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively.	50,571	14,520
Additional paid-in capital	94,883,532	82,770,313
Accumulated deficit	(67,634,031)	(61,554,889)
Total stockholders' equity	27,300,072	21,229,944
Total liabilities, convertible preferred stock and stockholders' equity	$ 29,943,836	$ 26,145,815

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	13,750,000	13,750,000
Preferred stock, shares issued (in shares)	0	12,376,329
Preferred stock, shares outstanding (in shares)	0	8,306,278
Preferred stock, liquidation value	$ 0	$ 16,778,682
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	50,572,001	14,519,629
Common stock, shares outstanding (in shares)	50,572,001	14,519,629

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
Research and development	$ 1,391,113	$ 1,179,544	$ 3,216,681	$ 2,187,115
General and administrative	1,660,630	1,795,886	3,158,469	3,349,025
Depreciation	26,709	5,790	54,727	12,393
Loss from operations	3,078,452	2,981,220	6,429,877	5,548,533
Other expense (income):
Interest (income) expense, net	(45,339)	18,889	(82,803)	74,608
Change in fair value of warrant liability		(23,387,850)		(10,468,176)
Warrant related expenses				10,225,846
Other financing expenses				2,870,226
(Loss) income before income tax benefit	(3,033,113)	20,387,741	(6,347,074)	(8,251,037)
Income tax benefit	(267,932)		(267,932)
Net (loss) income	(2,765,181)	20,387,741	(6,079,142)	(8,251,037)
Series A cumulative preferred dividends		(487,460)	(85,993)	(546,305)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock			(8,167,895)
Net (loss) income attributable to common stockholders	$ (2,765,181)	$ 19,900,281	$ (14,333,030)	$ (8,797,342)
Per share information:
Net (loss) income per share of common stock, basic (in dollars per share)	$ (0.05)	$ 0.88	$ (0.31)	$ (0.83)
Net (loss) income per share of common stock, diluted (in dollars per share)	$ (0.05)	$ (1)	$ (0.31)	$ (1.56)
Weighted average shares outstanding, basic (in shares)	50,546,021	10,828,063	46,357,478	10,582,521
Weighted average shares outstanding, diluted (in shares)	50,546,021	13,872,632	46,357,478	12,339,386

Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	8,306,278	14,519,629
Balance at Dec. 31, 2017		$ 14,520	$ 82,770,313	$ (61,554,889)		$ 21,229,944
Conversion of Series A convertible preferred stock to common stock (in shares)	(8,306,278)	8,306,278
Conversion of Series A convertible preferred stock to common stock		$ 8,306	(8,306)
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature		$ 11,668	(11,668)
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature (in shares)		11,668,421
Issuance of common stock related to accrued dividends		$ 1,032	1,147,275			1,148,307
Issuance of common stock related to accrued dividends (in shares)		1,032,219
Series A cumulative preferred dividends			(85,993)		$ (85,993)	(85,993)
Issuance of common stock and warrants, net of issuance costs		$ 15,000	10,402,520			10,417,520
Issuance of common stock and warrants, net of issuance costs (in shares)		15,000,000
Common stock issued for advisory services		$ 45	24,955			25,000
Common stock issued for advisory services (in shares)		45,454
Stock-based compensation expense			644,436			644,436
Net loss				(6,079,142)		(6,079,142)
Balance (in shares) at Jun. 30, 2018		50,572,001
Balance at Jun. 30, 2018		$ 50,571	$ 94,883,532	$ (67,634,031)		$ 27,300,072

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net loss	$ (6,079,142)	$ (8,251,037)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	54,727	12,393
Stock-based compensation expense	644,436	681,449
Common stock issued for advisory services	25,000
Warrant related expense, change in fair value, and other financing expenses		2,627,896
Deferred income taxes	(267,932)
Non-cash interest expense		85,309
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	185,487	(68,189)
Accounts payable, accrued expenses and other liabilities	(391,861)	(1,249,735)
Net cash used in operating activities	(5,829,285)	(6,161,914)
Cash flows used in investing activities:
Purchases of property and equipment		(64,002)
Purchase of certificate of deposit		(10,000,000)
Net cash used in investing activities		(10,064,002)
Cash flows provided by financing activities:
Payment of debt principal	(550,000)
Proceeds from the sale of common stock	10,846,062
Proceeds from the sale of Series A convertible preferred stock, net		22,129,774
Payment of offering costs	(428,542)	(43,311)
Net cash provided by financing activities	9,867,520	22,086,463
Net increase in cash and cash equivalents	4,038,235	5,860,547
Cash and cash equivalents at beginning of period	8,896,468	1,552,852
Cash and cash equivalents at end of period	12,934,703	7,413,399
Supplemental disclosure of cash flow information
Cash paid for interest	40,142
Supplemental disclosure of non-cash investing and financing activities:
Reclassification of accrued dividends related to the issuance of common stock to Series A convertible preferred stock holders	1,148,307
Purchases of property and equipment in accounts payable and accrued expenses		(348,286)
Offering costs in accounts payable and accrued expenses		(50,103)
Series A cumulative preferred dividends	(85,993)
Conversion of accrued dividends related to Series A convertible preferred stock		70,890
Series A Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Series A cumulative preferred dividends	$ (85,993)	$ (546,305)

Note 2 - Liquidity

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Liquidity [Text Block]

Liquidity

The Company has

not

generated any revenues from product sales and has funded operations primarily from the proceeds of public offerings, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities.

assurance can be given that any such financing will be available when needed or that the Company’s research and development efforts will be successful.

The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with

third

parties and other strategic alliances and business transactions. On

January 22, 2018,

the Company closed an underwritten public offering of

15,000,000

shares of the Company’s common stock, par value

$0.001

per share (“Common Stock”) and warrants to purchase

15,000,000

shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional

1,970,625

shares of Common Stock pursuant to the underwriter’s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of

$0.80

per share and warrant for total proceeds of approximately

$10.8

million. The warrants have an exercise price of

$0.80

per share and a term of

five

years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to

750,000

shares of Common Stock. The underwriter’s warrants have an exercise price of

$1.00,

a term of

five

years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into

21,006,918

shares of Common Stock (including accrued dividends paid-in-kind and issuance of shares in respect of the “make-whole” adjustment feature thereof).

The Company currently does

not

have any commitments to obtain additional funds and

may

be unable to obtain sufficient funding in the future on acceptable terms, if at all. On

March 2, 2018,

the Company received a written notice from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating the Company was

not

in compliance with Nasdaq Listing Rule

5550

(a)(

) because the bid price for the Company’s common stock had closed below

$1.00

per share for the previous

consecutive business days. In accordance with Nasdaq Listing Rule

5810

(c)(

)(A), the Company has

180

calendar days from the date of such notice, or until

August 29, 2018,

to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for the Company’s Common Stock must close at

$1.00

per share or more for a minimum of

consecutive business days. In the event the Company is unable to regain compliance, it could adversely affect the Company’s ability to obtain future funding. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with

third

parties to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it

may

receive lower consideration upon commercialization of such products than if it had

not

entered into such arrangements or if it entered into such arrangements at later stages in the product development process. At the Company’s

2018

Annual Meeting of Stockholders on

June 14, 2018,

the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to effect a reverse stock split of the shares of the Company’s common stock at a ratio of

not

less than

-to-

and

not

greater than

-to-

15,

with the exact ratio and effective time of the reverse stock split to be determined by the Company’s Board of Directors, if at all.

Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company believes its cash and cash equivalents at

June

30,

2018

are sufficient to fund operations into

September 2019.

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

3.	Basis of Presentation and Summary of Significant Accounting Policies

The Summary of Significant Accounting Policies included in the Company's Form

-K for the year ended

December

31,

2017,

filed with the Securities and Exchange Commission on

April 2, 2018

have

not

materially changed, except as set forth below.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form

-Q and Article

of Regulation S-

of the Securities and Exchange Commission (the “SEC”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim condensed consolidated financial statements) considered necessary to present fairly the Company’s financial position as of

June

30,

2018,

its results of operations for the

three

and

six

months ended

June

30,

2018

and

2017

and cash flows for the

six

months ended

June

30,

2018

and

2017.

Operating results for the

six

months ended

June

30,

2018

are

not

necessarily indicative of the results that

may

be expected for the year ending

December

31,

2018.

The unaudited interim condensed consolidated financial statements presented herein do

not

contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended

December

31,

2017

filed with the SEC on Form

-K on

April 2, 2018.

Use of Estimates

The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim condensed consolidated financial statements, actual results

may

materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim condensed consolidated financial statements in the period they are deemed necessary.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of

December

31,

2017,

the fair value of the Company’s outstanding Series B convertible debt was approximately

$0.6

million. The fair value of the convertible debt was determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level

of the fair value hierarchy.

Convertible Debt

Upon maturity of the Series B convertible debt during the

second

quarter of

2018,

the Company repaid the outstanding principal and interest of approximately

$0.6

million and

$40,000,

respectively. As such, the Company does

not

have any debt outstanding as of

June 30, 2018.

Intangible Asset and Goodwill

The Company has an intangible asset, RES-

529,

with a carrying value of

$8.6

million and goodwill, with a carrying value of

$6.9

million at both

June 30, 2018

and

December 31, 2017.

RES-

529

and goodwill are assessed for impairment on

October 1

of the Company’s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit. There were

impairment indicators or impairments to RES-

529

or goodwill during the

three

and

six

months ended

June 30, 2018

and

2017.

Income Taxes

December 22, 2017

the President of the United States signed into law the Tax Cuts and Jobs Act ("The

2017

Tax Act"), which resulted in significant changes from previous tax law. Among other things, the

2017

Tax Act reduced the federal corporate income tax rate to

21%

from

34%

effective

January 1, 2018

and also changed the net operating loss carryforwards’ period to now have an indefinite life for all net operating losses generated in

2018

and into the future. As a result of the change in net operating loss carryforward period, during the

six

months ended

June 30, 2018,

the Company recognized an income tax benefit of

$0.3

million to reflect indefinite deferred tax liabilities as a source of income against indefinite lived portions of the Company’s deferred tax assets.

Net (Loss) Income Per Common Share

For the

three

months ended

June 30, 2017,

the Company used the

two

-class method to compute net income per common share because the Company had issued securities (Series A convertible preferred stock) that entitle the holder to participate in dividends and earnings of the Company. Under this method, net income is reduced by any dividends earned during the period. The remaining earnings (undistributed earnings) were allocated to common stock and the Series A convertible preferred stock to the extent that the Series A convertible preferred stock was entitled to share in earnings as if all of the earnings for the period had been distributed. The total earnings allocated to common stock is then divided by the number of outstanding shares to which the earnings are allocated to determine the earnings per share. The

two

-class method is

not

applicable during periods with a net loss, as the holders of the convertible preferred stock would have

obligation to fund losses.

Diluted net (loss) income per common share is computed under the

two

-class method by using the weighted-average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options, unvested restricted stock, warrants, and convertible debt. In addition, the Company analyzed the potential dilutive effect of the previously outstanding convertible preferred stock under the “if-converted” method when calculating diluted earnings per share, in which it was assumed that the previously outstanding convertible preferred stock converted into common stock at the beginning of the period or when issued, if later. The Company reports the more dilutive of the approaches (

two

class or “if-converted”) as its diluted net (loss) income per share during the period.

For the periods in which the Company reported a net loss, there was

dilutive effect under either the

two

-class or “if-converted” method. For the

three

months ended

June 30, 2017,

the Company presented diluted net income per common share using the

two

-class method, which was more dilutive than the “if-converted” method.

For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include stock options, unvested restricted stock awards and warrants using the treasury stock method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would

not

have been incurred if the warrants had been converted into common stock. In addition, the Company considers the potential dilutive impact of its convertible debt instruments using the "if-converted" method.

The following table sets forth the computation of basic and diluted earnings per share:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Basic net (loss) income per common share calculation:
Net (loss) income	$	(2,765,181	)	$	20,387,741		$	(6,079,142	)	$	(8,251,037	)
Accretion of Series A cumulative preferred dividends		—			(487,460	)		(85,993	)		(546,305	)
Undistributed earnings allocated to participating securities		—			(10,416,153	)
Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common		—			—			(8,167,895	)		—
Net (loss) income attributable to common		(2,765,181	)		9,484,128			(14,333,030	)		(8,797,342	)

Weighted average common shares outstanding, basic		50,546,021			10,828,063			46,357,478			10,582,521
Net (loss) income per share of common, basic	$	(0.05	)	$	0.88		$	(0.31	)	$	(0.83	)

Diluted net income (loss) per common share calculation:
Net income (loss) attributable to common		(2,765,181	)		9,484,128			(14,333,030	)		(8,797,342	)
Add change in fair value of warrant liability		—			(23,387,850	)		—			(10,468,176	)
Diluted net loss		(2,765,181	)		(13,903,722	)		(14,333,030	)		(19,265,518	)
Weighted average common shares outstanding, basic		50,546,021			10,828,063			46,357,478			10,582,521
Add shares from dilutive warrants		—			3,044,569			—			1,756,865
Common stock equivalents		50,546,021			13,872,632			46,357,478			12,339,386
Diluted net loss per share of common	$	(0.05	)	$	(1.00	)	$	(0.31	)	$	(1.56	)

The following potentially dilutive securities outstanding as of

June

30,

2018

and

2017

have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:

	June 30,
	2018		2017
Convertible debt		—		774,886
Convertible preferred stock		—		10,449,338
Common stock warrants		31,312,512		457,721
Stock options		3,213,797		2,525,989
Unvested restricted stock awards		—		6,132
		34,526,309		14,214,066

Amounts in the table reflect the common stock equivalents of the noted instruments.

As a result of the offering of our common stock consummated in

January 2018,

all outstanding shares of the Company's Series A convertible preferred stock converted into shares common stock. See Note

Recent Accounting Pronouncements

June

2018,

the FASB issued ASU

2018

07,

Improvements to Nonemployee Share-Based Accounting,

which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC

505

and expands the scope of ASC

718

to include

all

share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC

718

associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU

2018

generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, for all (

) liability-classified nonemployee awards that have

not

been settled as of the adoption date and (

) equity-classified nonemployee awards for which a measurement date has

not

been established. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2019

and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

July

2017,

the FASB issued ASU

2017

11,

Earnings Per Share (Topic

260

); Distinguishing Liabilities from Equity (Topic

480

); Derivatives and Hedging (Topic

815

): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

The

first

part of this update addresses the complexity of accounting for certain financial instruments with down round features and the

second

part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2018

January 2017,

the FASB issued ASU

2017

04,

Intangibles-Goodwill and Other (Topic

350

)

which simplifies the accounting for goodwill impairments by eliminating step

from the goodwill impairment test. Instead, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. The standard will be effective for fiscal years beginning after

December

15,

2019,

including interim periods within such fiscal years. Early adoption is allowed for all entities as of

January 1, 2017,

for annual and any interim impairment tests occurring on or after

January 1, 2017.

The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

February 2016,

the FASB issued ASU

2016

02,

Leases (Topic

842

)

. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after

December

15,

2018,

including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

Note 6 - Stock-based Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

6.	Stock-Based Compensation

2015

Equity Plan

The Diffusion Pharmaceuticals Inc.

2015

Equity Plan, as amended (the

"2015

Equity Plan"), provides for increases to the number of shares reserved for issuance thereunder each

January 1,

equal to

4.0%

of the total shares of the Company’s common stock outstanding as of the immediately preceding

December 31,

unless a lesser amount is stipulated by the Compensation Committee of the Company's Board of Directors. Accordingly,

580,785

shares were added to the reserve as of

January 1, 2018,

which shares

may

be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the

2015

Equity Plan. As of

June

30,

2018,

there were

27,268

shares of common stock available for future issuance under the

2015

Equity Plan.

The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Research and development	$	16,274	$	24,072	$	32,646	$	67,404
General and administrative		303,495		290,994		611,790		614,045
Total stock-based compensation expense	$	319,769	$	315,066	$	644,436	$	681,449

The following table summarizes the activity related to all stock option grants to employees and non-employees for the

six

months ended

June

30,

2018:

	Number of Options			Weighted average exercise price per share		Weighted average remaining contractual life (in years)
Balance at January 1, 2018		2,555,989		$	7.32
Granted		660,000			1.02
Expired		(2,192	)		17.10
Outstanding at June 30, 2018		3,213,797		$	6.02		7.25
Exercisable at June 30, 2018		2,185,235		$	7.46		6.41

Non-employee Stock Options

Non-employee stock options are remeasured to fair value each period using a Black-Scholes option-pricing model until the options vest. The Company did

not

grant any stock options to non-employees during the

six

months ended

June

30,

2018.

The total fair value of non-employee stock options vested during the

three

months ended

June

30,

2018

and

2017

was approximately

$1,000

and

$12,000,

respectively. The total fair value of non-employee stock options vested during the

six

months ended

June

30,

2018

and

2017

was approximately

$2,000

and

$76,000,

respectively. At

June

30,

2018,

there were

8,137

unvested options subject to remeasurement and approximately

$3,000

of unrecognized compensation expense that will be recognized over a weighted-average period of

1.24

years.

Employee Stock Options

During the

six

months ended

June

30,

2018,

the Company granted

660,000

stock options to employees. The weighted average grant date fair value of stock option awards granted to employees was

$0.86

during the

six

months ended

June

30,

2018.

During the

three

months ended

June

30,

2018

and

2017

the Company recognized stock-based compensation expense of

$0.3

million and

$0.3

million, respectively. During the

six

months ended

June

30,

2018

and

2017,

the Company recognized stock-based compensation expense of

$0.6

million and

$0.6

million, respectively.

options were exercised during any of the periods presented. At

June

30,

2018,

there was

$2.5

million of unrecognized compensation expense that will be recognized over a weighted-average period of

5.0

years.

Options granted were valued using the Black-Scholes option-pricing model and the weighted average assumptions used to value the options granted during the

six

months ended

June 30, 2018

and

2017

were as follows:

	2018			2017
Expected term (in years)		5.57			5.68
Risk-free interest rate		2.4	%		2.0	%
Expected volatility		114.7	%		114.9	%
Dividend yield		—	%		—	%

Restricted Stock Awards

As of

June

30,

2018,

there were

unvested shares of restricted stock. During the

three

months ended

June

30,

2018

and

2017,

there were

1,533

and

1,533

shares that vested, respectively and the Company recognized stock-based compensation expense of approximately

$3,000

and

$3,000,

respectively. During the

six

months ended

June

30,

2018

and

2017,

there were

3,066

and

3,072

shares that vested, respectively and the Company recognized stock-based compensation expense of approximately

$6,000

and

$6,000,

respectively.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

-Q and Article

of Regulation S-

June

30,

2018,

its results of operations for the

three

and

six

months ended

June

30,

2018

and

2017

and cash flows for the

six

months ended

June

30,

2018

and

2017.

Operating results for the

six

months ended

June

30,

2018

are

not

necessarily indicative of the results that

may

be expected for the year ending

December

31,

2018.

The unaudited interim condensed consolidated financial statements presented herein do

not

December

31,

2017

filed with the SEC on Form

-K on

April 2, 2018.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

may

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

December

31,

2017,

the fair value of the Company’s outstanding Series B convertible debt was approximately

$0.6

million. The fair value of the convertible debt was determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level

of the fair value hierarchy.

Debt, Policy [Policy Text Block]

Convertible Debt

Upon maturity of the Series B convertible debt during the

second

quarter of

2018,

the Company repaid the outstanding principal and interest of approximately

$0.6

million and

$40,000,

respectively. As such, the Company does

not

have any debt outstanding as of

June 30, 2018.

Goodwill and Intangible Assets, Policy [Policy Text Block]

Intangible Asset and Goodwill

The Company has an intangible asset, RES-

529,

with a carrying value of

$8.6

million and goodwill, with a carrying value of

$6.9

million at both

June 30, 2018

and

December 31, 2017.

RES-

529

and goodwill are assessed for impairment on

October 1

of the Company’s fiscal year or more frequently if impairment indicators exist. The Company has a single reporting unit and all goodwill relates to that reporting unit. There were

impairment indicators or impairments to RES-

529

or goodwill during the

three

and

six

months ended

June 30, 2018

and

2017.

Income Tax, Policy [Policy Text Block]

Income Taxes

December 22, 2017

the President of the United States signed into law the Tax Cuts and Jobs Act ("The

2017

Tax Act"), which resulted in significant changes from previous tax law. Among other things, the

2017

Tax Act reduced the federal corporate income tax rate to

21%

from

34%

effective

January 1, 2018

and also changed the net operating loss carryforwards’ period to now have an indefinite life for all net operating losses generated in

2018

and into the future. As a result of the change in net operating loss carryforward period, during the

six

months ended

June 30, 2018,

the Company recognized an income tax benefit of

$0.3

million to reflect indefinite deferred tax liabilities as a source of income against indefinite lived portions of the Company’s deferred tax assets.

Earnings Per Share, Policy [Policy Text Block]

Net (Loss) Income Per Common Share

For the

three

months ended

June 30, 2017,

the Company used the

two

-class method is

not

applicable during periods with a net loss, as the holders of the convertible preferred stock would have

obligation to fund losses.

Diluted net (loss) income per common share is computed under the

two

class or “if-converted”) as its diluted net (loss) income per share during the period.

For the periods in which the Company reported a net loss, there was

dilutive effect under either the

two

-class or “if-converted” method. For the

three

months ended

June 30, 2017,

the Company presented diluted net income per common share using the

two

-class method, which was more dilutive than the “if-converted” method.

not

The following table sets forth the computation of basic and diluted earnings per share:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Basic net (loss) income per common share calculation:
Net (loss) income	$	(2,765,181	)	$	20,387,741		$	(6,079,142	)	$	(8,251,037	)
Accretion of Series A cumulative preferred dividends		—			(487,460	)		(85,993	)		(546,305	)
Undistributed earnings allocated to participating securities		—			(10,416,153	)
Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common		—			—			(8,167,895	)		—
Net (loss) income attributable to common		(2,765,181	)		9,484,128			(14,333,030	)		(8,797,342	)

Weighted average common shares outstanding, basic		50,546,021			10,828,063			46,357,478			10,582,521
Net (loss) income per share of common, basic	$	(0.05	)	$	0.88		$	(0.31	)	$	(0.83	)

Diluted net income (loss) per common share calculation:
Net income (loss) attributable to common		(2,765,181	)		9,484,128			(14,333,030	)		(8,797,342	)
Add change in fair value of warrant liability		—			(23,387,850	)		—			(10,468,176	)
Diluted net loss		(2,765,181	)		(13,903,722	)		(14,333,030	)		(19,265,518	)
Weighted average common shares outstanding, basic		50,546,021			10,828,063			46,357,478			10,582,521
Add shares from dilutive warrants		—			3,044,569			—			1,756,865
Common stock equivalents		50,546,021			13,872,632			46,357,478			12,339,386
Diluted net loss per share of common	$	(0.05	)	$	(1.00	)	$	(0.31	)	$	(1.56	)

The following potentially dilutive securities outstanding as of

June

30,

2018

and

2017

have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:

	June 30,
	2018		2017
Convertible debt		—		774,886
Convertible preferred stock		—		10,449,338
Common stock warrants		31,312,512		457,721
Stock options		3,213,797		2,525,989
Unvested restricted stock awards		—		6,132
		34,526,309		14,214,066

Amounts in the table reflect the common stock equivalents of the noted instruments.

As a result of the offering of our common stock consummated in

January 2018,

all outstanding shares of the Company's Series A convertible preferred stock converted into shares common stock. See Note

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

June

2018,

the FASB issued ASU

2018

07,

Improvements to Nonemployee Share-Based Accounting,

which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC

505

and expands the scope of ASC

718

to include

all

share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC

718

associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU

2018

) liability-classified nonemployee awards that have

not

been settled as of the adoption date and (

) equity-classified nonemployee awards for which a measurement date has

not

been established. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2019

July

2017,

the FASB issued ASU

2017

11,

Earnings Per Share (Topic

260

); Distinguishing Liabilities from Equity (Topic

480

); Derivatives and Hedging (Topic

815

The

first

part of this update addresses the complexity of accounting for certain financial instruments with down round features and the

second

part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2018

January 2017,

the FASB issued ASU

2017

04,

Intangibles-Goodwill and Other (Topic

350

)

which simplifies the accounting for goodwill impairments by eliminating step

December

15,

2019,

including interim periods within such fiscal years. Early adoption is allowed for all entities as of

January 1, 2017,

for annual and any interim impairment tests occurring on or after

January 1, 2017.

The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

February 2016,

the FASB issued ASU

2016

02,

Leases (Topic

842

)

. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after

December

15,

2018,

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block]	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 57%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 144%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise price </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">per share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 57%;">Common stock warrants issued prior to 2016</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37.50</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$49.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 13%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018 through 2019</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 57%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,555,887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22</div></td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 13%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 57%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the common stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,720,625</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 13%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 57%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,312,512</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div>

Note 2 - Liquidity (Details Textual) $ / shares in Units, $ in Millions			1 Months Ended
	Jun. 14, 2018	Jan. 22, 2018 USD ($) $ / shares shares	Jan. 31, 2018 USD ($) $ / shares shares	Jun. 30, 2018 $ / shares	Dec. 31, 2017 $ / shares
Common Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001	$ 0.001
Conversion From Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued \| shares		21,006,918	21,006,918
Maximum [Member] \| Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15
Minimum [Member] \| Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2
Warrants Issued in Connection with the January 2018 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		15,000,000	15,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80	$ 0.80
Class of Warrant or Right, Term		5 years
Warrants Issued in Connection with the January 2018 Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				1
Warrants Issued in Connection with the January 2018 Offering [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.80
Additional Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.80
Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Underwriter Warrants [Member] \| H.C Wainwright & Co., LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Class of Warrant or Right, Term		5 years
Underwriter Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		750,000	750,000
Class of Warrant or Right, Term			5 years
January 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues \| shares		15,000,000	15,000,000
Share Price		$ 0.80
Proceeds from Issuance or Sale of Equity, Total \| $		$ 10.8	$ 10.8
January 2018 Offering [Member] \| Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		1,970,625

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Repayments of Long-term Debt, Total			$ 550,000
Interest Paid, Excluding Capitalized Interest, Operating Activities			40,142
Goodwill, Ending Balance	$ 6,929,258		6,929,258		$ 6,929,258
Impairment of Intangible Assets (Excluding Goodwill), Total	0	$ 0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%		34.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability			$ (300,000)
RES-529 [Member]
Intangible Assets, Net (Excluding Goodwill), Total	8,600,000		8,600,000
Convertible Note, Series B [Member]
Repayments of Long-term Debt, Total			600,000
Interest Paid, Excluding Capitalized Interest, Operating Activities			40,000
Convertible Debt, Total	$ 0		$ 0
Fair Value, Inputs, Level 3 [Member] \| Convertible Note, Series B [Member]
Convertible Debt, Fair Value Disclosures					$ 600,000

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net (loss) income	$ (2,765,181)	$ 20,387,741	$ (6,079,142)	$ (8,251,037)
Accretion of Series A cumulative preferred dividends		(487,460)	(85,993)	(546,305)
Undistributed earnings allocated to participating securities		(10,416,153)
Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common			(8,167,895)
Net (loss) income attributable to common stockholders	$ (2,765,181)	$ 19,900,281	$ (14,333,030)	$ (8,797,342)
Weighted average shares outstanding, basic (in shares)	50,546,021	10,828,063	46,357,478	10,582,521
Net (loss) income per share of common stock, basic (in dollars per share)	$ (0.05)	$ 0.88	$ (0.31)	$ (0.83)
Add change in fair value of warrant liability		$ (23,387,850)		$ (10,468,176)
Diluted net loss	$ (2,765,181)	$ (13,903,722)	$ (14,333,030)	$ (19,265,518)
Add shares from dilutive warrants (in shares)		3,044,569		1,756,865
Common stock equivalents (in shares)	50,546,021	13,872,632	46,357,478	12,339,386
Net (loss) income per share of common stock, diluted (in dollars per share)	$ (0.05)	$ (1)	$ (0.31)	$ (1.56)

Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accrued interest payable		$ 37,415
Accrued Series A dividends		1,062,314
Accrued payroll and payroll related expenses	328,581	312,221
Accrued professional fees	55,993	122,711
Accrued clinical studies expenses	60,120	63,350
Other accrued expenses	67,552	30,840
Total	$ 512,246	$ 1,628,851

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 22, 2018	Jan. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock Issued During Period, Shares, Conversion of Convertible Securities		8,306,278
Common Stock Dividends, Shares		1,032,219
Stock Issued During Period, Shares, Make-whole Adjustment		11,668,421
Dividends, Make-whole Adjustment		$ 8,200,000			$ (8,167,895)
Class of Warrant or Right, Exercised					0
Warrant [Member]
Class of Warrant or Rights, Expired					411,721
Conversion From Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued	21,006,918	21,006,918
Warrants Issued in Connection with the January 2018 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,000,000	15,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80	$ 0.80
Class of Warrant or Right, Term	5 years
Warrants Issued in Connection with the January 2018 Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1		$ 1
Option Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,250,000
Additional Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Granted		1,970,625
Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Underwriter Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	750,000	750,000
Class of Warrant or Right, Term		5 years
January 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	15,000,000	15,000,000
Proceeds from Issuance or Sale of Equity, Total	$ 10,800,000	$ 10,800,000
Stock Issued During Period, Shares, Issued for Services		2,250,000
January 2018 Offering [Member] \| Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,970,625

Note 6 - Stock-based Compensation (Details Textual) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 01, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				660,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 2,500,000		$ 2,500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				5 years
Allocated Share-based Compensation Expense, Total		319,769	$ 315,066	$ 644,436	$ 681,449
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				0	0
Non-employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 1,000	12,000	$ 2,000	$ 76,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance		8,137		8,137
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 3,000		$ 3,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 87 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				660,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 0.86
Allocated Share-based Compensation Expense, Total		300,000	300,000	$ 600,000	600,000
Restricted Stock [Member]
Allocated Share-based Compensation Expense, Total		$ 3,000	$ 3,000	$ 6,000	$ 6,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance		0		0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		1,533	1,533	3,066	3,072
Restorgenex Corporation 2015 Equity Incentive Plan [Member]
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis				4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	580,785
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		27,268		27,268

Note 6 - Stock-based Compensation - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Options outstanding, number (in shares) \| shares	2,555,989
Options outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 7.32
Granted (in shares) \| shares	660,000
Granted, weighted-average exercise price (in dollars per share) \| $ / shares	$ 1.02
Expired (in shares) \| shares	(2,192)
Expired, weighted-average exercise price (in dollars per share) \| $ / shares	$ 17.10
Options outstanding, number (in shares) \| shares	3,213,797
Options outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 6.02
Options outstanding, weighted-average remaining contractual life (Year)	7 years 91 days
Exercisable (in shares) \| shares	2,185,235
Exercisable, weighted-average exercise price (in dollars per share) \| $ / shares	$ 7.46
Exercisable, weighted-average remaining contractual life (Year)	6 years 149 days

Note 7 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)	Jun. 30, 2018 USD ($)
2018	$ 56,519
2019	114,409
2020	116,464
2021	118,519
2022	39,735
Total	$ 445,646

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares	Jun. 30, 2018	Jan. 31, 2018	Jan. 22, 2018
Common stock warrants, outstanding (in shares)	31,312,512
Warrants issued before 2016 [Member]
Common stock warrants, outstanding (in shares)	36,000
Warrants issued before 2016 [Member] \| Minimum [Member]
Range of exercise price (in dollars per share)	$ 37.50
Warrants issued before 2016 [Member] \| Maximum [Member]
Range of exercise price (in dollars per share)	$ 49
Warrants Attached to Series A Convertible Preferred Stock [Member]
Common stock warrants, outstanding (in shares)	13,555,887
Range of exercise price (in dollars per share)	$ 2.22
Warrants Issued in Connection with the January 2018 Offering [Member]
Common stock warrants, outstanding (in shares)	17,720,625
Range of exercise price (in dollars per share)		$ 0.80	$ 0.80
Warrants Issued in Connection with the January 2018 Offering [Member] \| Minimum [Member]
Range of exercise price (in dollars per share)	0.80
Warrants Issued in Connection with the January 2018 Offering [Member] \| Maximum [Member]
Range of exercise price (in dollars per share)	$ 1

Note 6 - Stock-based Compensation - Fair Value Assumptions (Details)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Expected term (Year)	5 years 208 days	5 years 248 days
Risk-free interest rate	2.40%	2.00%
Expected volatility	114.70%	114.90%
Dividend yield

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Research and Development Expense, Total	$ 1,391,113	$ 1,179,544	$ 3,216,681	$ 2,187,115
Arrangement With Clinical Research Organization [Member]
Research and Development Expense, Total	400,000		1,200,000
Prepaid Research and Development Expense	500,000		500,000
Charlottesville, Virginia [Member] \| Building [Member]
Operating Leases, Rent Expense, Net, Total	$ 28,000	$ 35,000	$ 56,000	$ 52,000

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Anti-dilutive securities (in shares)	34,526,309	14,214,066
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		774,886
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities (in shares)		10,449,338
Warrant [Member]
Anti-dilutive securities (in shares)	31,312,512	457,721
Employee Stock Option [Member]
Anti-dilutive securities (in shares)	3,213,797	2,525,989
Restricted Stock [Member]
Anti-dilutive securities (in shares)		6,132